Connect with us

Technology

Study published in the New England Journal of Medicine AI Concludes that the Sepsis ImmunoScore™, the First FDA-Authorized AI Tool for Sepsis, has both significant Diagnostic and Predictive Power

Published

1 year ago

on

Groundbreaking NEJM AI Study Highlights the Ability of Prenosis’ Sepsis ImmunoScore™ to Holistically Predict Adverse Outcomes, Ushering in a New Era of Predictive Sepsis Tools Powered by AI

CHICAGO, Dec. 4, 2024 /PRNewswire/ — A new study published in the New England Journal of Medicine AI (NEJM AI) concluded the Sepsis ImmunoScore™, the first FDA-authorized AI diagnostic for sepsis, has high accuracy for the diagnosis of sepsis and for prediction of key adverse patient outcomes, concretely demonstrating the benefit of AI to inform sepsis care. Sepsis, an overactive immune response to infection, costs the U.S. healthcare system billions of dollars annually and claims the lives of at least 350,000 people each year—more than all cancers combined.

The peer-reviewed study—FDA-Authorized AI/ML Tool for Sepsis Prediction: Development and Validation—found the Sepsis ImmunoScore™ has high accuracy for sepsis diagnosis and simultaneously predicted critical outcomes, including mortality during hospitalization, length of stay before discharge, ICU admission, need for mechanical ventilation, and use of vasopressors. This represents the first time an FDA-authorized tool for sepsis can predict all of these critical outcomes simultaneously.

This milestone publication underscores the potential of Prenosis Inc.’s Sepsis ImmunoScore™ to transform sepsis management by presenting providers with trustworthy predictive information, allowing them to shift from a reactive to a proactive approach to care.

While single biomarkers, such as Procalcitonin (PCT), have been valuable tools in diagnosing sepsis for over two decades, they have limitations when trying to predict the future. The study demonstrated the combination of multidimensional inputs—vital signs, lab data, and sepsis-specific biomarkers—into a comprehensive AI-driven tool provides more reliable diagnostic information and is predictive of future patient outcomes.

“The Sepsis ImmunoScore™ is the first FDA-authorized sepsis AI algorithm that functions by embedding in the EMR and is approved to aid providers in the identification and assessment of patients with sepsis,” said Nathan I. Shapiro, MD, MPH, a Professor of Emergency Medicine at Harvard Medical School and attending physician in the Department of Emergency Medicine at Beth Israel Deaconess Medical Center, and the paper’s corresponding author1.

“For too long, clinicians have struggled with the early and accurate prediction of adverse outcomes due to sepsis, a complex, rapidly progressing condition,” said Bobby Reddy, Jr., Prenosis Co-Founder and CEO. “By delivering FDA validated AI results with transparency and explainability for clinicians, tools like the Sepsis ImmunoScore™ offer critical insights to improve patient outcomes.”

“Hospitals and clinicians now have access to the first-ever FDA-authorized, peer-reviewed AI solution that provides unmatched insights into sepsis risk and prediction of the negative outcomes associated with sepsis,” said Akhil Bhargava, the study’s lead author. “This study confirmed that AI, when validated, can be a reliable, comprehensive tool to assist providers with identification of patients at high risk of sepsis and prediction of sepsis-related adverse outcomes,” added Bhargava, Prenosis’ Senior Data Scientist — Applied Machine Learning.

About the Sepsis ImmunoScore™

FDA-authorized via the De Novo pathway in April 2024, the Sepsis ImmunoScore™ outputs a combination of both diagnostic and predictive information previously unavailable in a legally marketed device for sepsis. Unlike early warning systems that alert clinicians to potential sepsis with high amounts of false positives, leading to alert fatigue, the Sepsis ImmunoScore™ delivers actionable and trustworthy insights. The Sepsis ImmunoScore™ works in concert with a clinician’s suspicion of serious infection, providing information exactly when needed for decision-making.

The Sepsis ImmunoScore™ was built using Prenosis’ Immunix™ platform, which enables precision medicine in acute care. Immunix™ facilitates the development and validation of new precision solutions, such as AI biomarkers, and their real-time implementation. Over a decade of collaboration with more than ten U.S. partner hospitals, Prenosis used Immunix™ to build a proprietary biobank and dataset of over 113,000 blood samples from more than 28,000 patients. Prenosis merges biological data extracted from these samples with clinical information from Electronic Medical Records, creating the world’s largest biological-clinical dataset for acute care patients with suspected serious infections. This dataset enables the development of AI algorithms to detect rapid immune responses and recommend personalized therapies in real time in hospitals and emergency departments.

About Prenosis

Prenosis Inc. is an artificial intelligence company pioneering precision medicine in acute care.  We believe healthcare should be tailored to individual biology. Our data-driven approach to fast-moving biology in acute care is ushering in a new era of precision medicine. Powered by our Immunix™ precision medicine platform, we generate proprietary biological insights that drive the development of precision products and enable real-time delivery of optimal therapy. With Immunix™, we created and validated the first FDA-authorized AI biomarker for sepsis, the Sepsis ImmunoScore™.

For more information, visit: www.prenosis.com

1 Disclosure: Shapiro holds private equity in and consults for Prenosis.

View original content to download multimedia:https://www.prnewswire.com/news-releases/study-published-in-the-new-england-journal-of-medicine-ai-concludes-that-the-sepsis-immunoscore-the-first-fda-authorized-ai-tool-for-sepsis-has-both-significant-diagnostic-and-predictive-power-302321806.html

SOURCE Prenosis

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World’s Largest Trading Market

Published

59 minutes ago

on

April 20, 2026

By

White-label prop firm operators can now offer equities alongside forex, futures, and crypto, all inside one tech stack, at no additional cost.

BOCA RATON, Fla., April 20, 2026 /PRNewswire/ — PropAccount.com, which is powered by FPFX Tech, and operates as the world’s largest white-label prop firm provider, has announced the addition of equities trading to its offering, bringing the world’s largest financial market within reach of every prop firm operator on its network.

With equities now supported inside the PropAccount.com ecosystem, white-label partners can offer equities trading challenges in single-session and swing-trading varieties.

One Platform. Four Asset Classes.

PropAccount.com is recognized as one of the prop trading industry’s most comprehensive infrastructure solutions, supporting forex, futures, and crypto across leading platforms, including DXtrade, Match-Trader, cTrader, Rithmic, and Tradovate. The addition of equities completes the grand slam of assets.

For existing PropAccount.com partners, equities trading slots directly into the same infrastructure that already handles trader onboarding, challenges, automated risk rules, account management, KYC, and payments. There is nothing new to configure, no new vendor to manage, and no new cost to absorb.

For new operators entering the industry, the launch path is equally direct. PropAccount’s white-label model allows operators to go live in as little as seven days, with equities available alongside the full suite of supported markets.

A Market Too Large to Ignore

According to the Securities Industry and Financial Markets Association, U.S. equity market capitalization was at $68.2 trillion at year-end 2025, with daily trading volume averaging a record 18.6 billion shares. The numbers speak for themselves. Millions of traders worldwide focus on equities as a core part of their strategy, and the prop firm ecosystem has not offered this asset class – until now. PropAccount.com’s expansion into equities allows operators to reach this audience directly, building programs designed specifically for traders without fragmenting their existing infrastructure.

Wider Audience for Operators

For operators, the practical opportunity is audience expansion. Many equities traders have never engaged with a prop firm because no prop firm has spoken to them. Equities support on PropAccount.com changes that calculus, giving operators a direct path to a segment of the trading community that has largely been left out of the prop firm model.

The PropAccount platform handles risk monitoring, drawdown controls, scaling rules, automated payouts, trader dashboards, CRM, affiliate systems, and KYC: every operational layer required to run a professional prop firm. Adding a fourth asset class to that foundation required no new architecture. It was built to support it.

“Equities are the largest traded market in the world, and traders have been underserved by the retail prop industry for too long. Adding equities to our tech stack means our operators can now reach this audience directly with the equities they trade, without forcing them to adjust to equity CFDs.” – Justin Hertzberg, CEO of PropAccount.com

About PropAccount.com

PropAccount.com is the white-label prop firm infrastructure provider powered by FPFX Tech, the leader in prop trading technology. The platform enables entrepreneurs, trading educators, influencers, and IBs to launch fully branded prop firms in as little as seven days, using enterprise-grade technology covering trading platforms, risk tools, payments, KYC, affiliate systems, trader dashboards, and capital backing.

Contact:
Scott
***@propaccount.com

Photo(s):
https://www.prlog.org/13140490

Press release distributed by PRLog

View original content:https://www.prnewswire.com/news-releases/propaccountcom-adds-equities-to-its-multi-asset-prop-firm-platform-opening-the-door-to-the-worlds-largest-trading-market-302747650.html

SOURCE Propaccount.com

Continue Reading

Technology

Health Karma Launches PersonalCare Bundles to Address America’s Underinsured Crisis, Unlocking Immediate Revenue Opportunity

Published

59 minutes ago

on

April 20, 2026

By

LEESBURG, Fla., April 20, 2026 /PRNewswire-PRWeb/ — Health Karma Inc., a leader in proactive well-being and behavioral health solutions, today announced the national rollout of its Health Karma PersonalCare™ Bundles, a new product line designed to meet the urgent healthcare access needs of millions of uninsured and underinsured Americans – particularly independent contractors, part-time, and hourly workers.

Developed over the past two years and fully integrated into Health Karma’s proprietary mobile platform, the PersonalCare Bundles represent a scalable, direct-to-consumer healthcare access solution that is already gaining rapid traction across broker networks nationwide.

A Massive, Underserved Market – The launch comes at a critical time in the U.S. healthcare landscape:

Nearly 23% of working-age adults are underinsured, facing high deductibles and out-of-pocket costsApproximately 24 million Americans remain completely uninsuredMillions more experience gaps in coverage annuallyAverage deductibles now exceed $4,000, with marketplace plans reaching as high as $7,400+

These realities leave a significant portion of the workforce, especially gig workers and part-time employees, effectively locked out of timely, affordable care.

“We Are Not Insurance — We Are Access”:

Health Karma’s PersonalCare Bundles are not insurance products. Instead, they provide immediate, affordable access to healthcare services through a simple, app-based experience. Users can connect 24/7 with licensed physicians, Master’s-level behavioral health clinicians, receive diagnoses, and obtain prescriptions often at zero out-of-pocket cost within hours. One early user shared their experience after enrolling through a broker partner: “I had a severe breakout and couldn’t reach my primary doctor. Through the app, I spoke with a physician within an hour, received a prescription, and paid $0 for both the consultation and medication. The entire process took less than two hours and solved my problem completely.”

Immediate Revenue, Proven Demand – Health Karma reports strong early validation of the product:

Zero pushback from broker distribution channelsInitial pilot groups saw 127 immediate sign-upsNationwide rollout underway through thousands of insurance brokers and independent agentsAll bundles, even the entry-level bundles, generate significant and sustainable recurring revenue for Health Karma

With a growing network of over 100 experienced brokers ready to deploy, the Company anticipates rapid expansion in the coming quarters.

Flexible Distribution Model – The PersonalCare Bundles are uniquely positioned for mass adoption:

Available direct-to-consumer without employer sponsorshipNo requirement for licensed insurance agents to sellEasily deployable for employers via simple group enrollment and monthly billingAccessible across mobile, tablet, and desktop, with a seamless app-based interface

Part of a Broader Growth Strategy – This launch complements Health Karma’s expanding footprint across multiple high-impact verticals, including:

UniversitiesHealthcare and health benefit providersJustice-Impacted Reentry ProgramsFirst Responders and VeteransNative American tribal healthcare programsWorkplace violence response programsWorkers’ compensation solutions

Technology-Driven Expansion:

To accelerate adoption, Health Karma is preparing a 90-day rollout strategy leveraging advanced AI, SEO, and targeted digital marketing to reach high-need populations such as small business owners, gig economy workers, and uninsured individuals.

Executive Commentary:

Travis H. Jackson, CEO of Health Karma, stated: “This is one of the most important products we’ve developed. It directly addresses a massive and growing gap in the U.S. healthcare system. The demand is immediate, the feedback has been overwhelmingly positive, and the revenue potential is significant. We are moving aggressively to scale distribution and ensure this solution reaches the millions of people who need it most.”

About Health Karma Inc.

Health Karma Inc. delivers proactive well-being, behavioral health, and injury triage solutions through its innovative “1st Moment” model providing immediate, comprehensive support whenever and wherever individuals need care. By combining technology, accessibility, and real-time intervention, Health Karma is redefining how healthcare is delivered across both public and private sectors.

Learn more: www.HealthKarmaGroup.com

Media Contact: IR@healthkarmagroup.com

Media Contact

Robert Hood, Health Karma Inc, 1 9406342860, bob@healthkarmagroup.com, https://www.healthkarmagroup.com/ 

View original content:https://www.prweb.com/releases/health-karma-launches-personalcare-bundles-to-address-americas-underinsured-crisis-unlocking-immediate-revenue-opportunity-302746750.html

SOURCE Health Karma Inc

Continue Reading

Technology

V2X to Announce First Quarter 2026 Financial Results

Published

59 minutes ago

on

April 20, 2026

By

RESTON, Va., April 20, 2026 /PRNewswire/ — V2X, Inc., (NYSE: VVX), a leading provider of global mission solutions, will report first quarter 2026 financial results on Monday, May 4, 2026, after market close. Senior management will conduct a conference call at 4:30 p.m. ET that same day.

U.S.-based participants may dial in to the conference call at 877-300-8521, while international participants may dial 412-317-6026. A live webcast of the conference call as well as an accompanying slide presentation will be available at https://app.webinar.net/Q291YZzYJpN and on the Investors section of the V2X website at https://gov2x.com/.

A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through May 18, 2026, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 10208314.  

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact 
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact 
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-to-announce-first-quarter-2026-financial-results-302747820.html

SOURCE V2X, Inc.

Continue Reading

Trending